Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease.
Heslop
H
H
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston 77030-2399, USA.
Rooney
C
C
Brenner
M
M
Krance
R
R
Carrum
G
G
Gahn
B
B
Bollard
C
C
Khan
S
S
Gee
A
A
Popat
U
U
Gresik
M
M
Przepiorka
D
D
Kuehnle
I
I
Grilley
B
B
D016026:Bone Marrow Transplantation / Q000379:methods*; D002460:Cell Line; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005240:Feasibility Studies; D005260:Female; D015316:Genetic Therapy; D004854:Herpesvirus 4, Human / Q000235:genetics* / Q000276:immunology; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008297:Male; D009355:Neomycin / Q000378:metabolism*; D012008:Recurrence; D013602:T-Lymphocytes, Cytotoxic / Q000378:metabolism*
D009355:Neomycin